Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis


Hepatocellular carcinoma (HCC) is the most common tumor in the adult liver, with high relapse and mortality rates despite diverse treatment modalities. In this study, nicotinamide N-methyltransferase (NNMT), a key enzyme in drug metabolism, was investigated as a potential prognostic factor.

Methods: Frozen tumors and non-cancerous surrounding tissues from 120 patients with primary HCC were studied.

Expressions of NNMT and internal control genes were measured by real-time reverse-transcription PCR (RT-PCR). The relationship of NNMT mRNA level with clinicopathologic parameters and clinical outcome was evaluated.

Results: NNMT mRNA level is markedly reduced in HCCs compared to non-cancerous surrounding tissues (P <0.0001), and NNMT expression in tumors was significantly correlated with tumor stage (P = 0.010).

Moreover, stratification of patients based on tumor NNMT mRNA levels revealed that the patients who expressed higher NNMT mRNA levels tended to have a shorter overall survival (OS) time (P = 0.053) and a significantly shorter disease-free survival (DFS) time (P = 0.016). Both NNMT expression (P = 0.0096) and tumor stage (P = 0.0017) were found to be significant prognostic factors for DFS in a multivariate analysis.

Conclusions: The results of this study indicated that NNMT gene expression is associated with tumor stage and DFS time in HCC cases.

Because of the broad substrate specificity of NNMT, which could alter the efficacy and adverse effects of chemotherapy, NNMT merits further investigation regarding its role as a prognostic factor with a larger cohort of HCC patients.

Author: Jongmin Kim, Seok Joo Hong, Eun Kyung Lim, Yun-Suk Yu, Seung Whan Kim, Ji Hyeon Roh, In-Gu Do, Jae-Won Joh and Dae Shick Kim
Credits/Source: Journal of Experimental &Clinical Cancer Research 2009, 28:20



Published on: 2009-02-16



Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.

Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo



Comments Page 0 of 0
There are currently 0 comments to display.

 


+ Add New Comment


Custom Search

Username
Password










© 2012 7thSpace Interactive
All Rights Reserved - About | Disclaimer | Helpdesk
There are currently 41672 people browsing 7thSpace